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Background: Among women in the United States, breast cancer accounts for 30% of all new 
cancer diagnoses and is the second leading cause of cancer-related deaths. Obesity affects more 
than 40% of the American adult population and is a well-established risk factor for breast cancer. 
Therefore, weight loss interventions for obesity are of great importance. While there is evidence 
that both dietary and surgical weight loss approaches may reduce cancer risk, it is not yet 
understood how these interventions differentially affect breast cancer outcomes. This honors 
thesis aimed to compare metabolic, inflammatory, and cecal microbial profiles to elucidate 
differences between dietary and surgical weight loss interventions for obesity in a mouse model 
of breast cancer. 
Methods: Female C57BL/6NCrl mice were maintained on either 10 kcal% low-fat or 60 kcal% 
high-fat diet regimens, then randomized to receive either: a) sham surgery and continuation of 
the low-fat diet (CON); b) sham surgery and continuation of the high-fat diet (DIO); c) sham 
surgery with switch from the high-fat diet to a chronic calorie restriction diet (CCR); d) sham 
surgery with switch from the high-fat diet to an intermittent calorie restriction diet (ICR); or e) 
vertical sleeve gastrectomy with switch from the high-fat to low-fat diet (VSG). To establish 
metabolic and inflammatory profiles for each diet group prior to E0771 cell injections, serum 
cytokines, chemokines, and metaboendocrine hormones were measured using Luminex assays. 
Cecal microbial communities collected at tumor endpoint were evaluated via 16S rRNA gene 
sequencing. 
Results: CCR and ICR weight loss interventions significantly reduced tumor mass relative to all 
other groups. Serum C-X-C motif chemokine ligand(CXCL)13 and plasminogen activator 
inhibitor(PAI)-1 were reduced in CCR and ICR mice, but elevated in VSG mice. Serum PAI-1 
and gross body weight loss were found to predict final tumor mass independent of diet group. 
Cecal microbial composition was distinct across all groups, and the number of observed 
sequence variants (SVs) was lower in VSG mice compared with CON, DIO, and ICR mice. 
Among CCR and ICR mice, 7 genera were differentially abundant compared with VSG mice. 
Most of these genera, as well as the number of observed SVs, were significantly associated with 
final tumor mass. 
Conclusions: These data suggest that serum CXCL13, serum PAI-1, gross body weight loss, and 
cecal microbial community composition may distinguish dietary from surgical weight loss 
interventions, as well as contribute to the improved anticancer effects observed in the calorie 
restriction groups. Understanding the impact of weight loss on these physiological factors and 
determining if these factors act independently or in combination with each other may eventually 
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Breast Cancer Prevalence and Mortality 
Among American women, breast cancer is the most commonly diagnosed cancer, 
accounting for 30% of all new cancer cases, and incidence is on the rise.1,2 In 2019, it was 
projected that there would be 268,600 new invasive breast cancer cases resulting in 41,760 
deaths, making breast cancer the second leading cause of cancer-related mortality in women in 
the United States.1,2 Over the life course, there is a 1 in 8 chance that a woman in the United 
States will develop invasive breast cancer.2 Additionally, although the gap is narrowing, racial 
disparities in breast cancer persist.1–3 While non-Hispanic white women have the highest 
incidence, non-Hispanic black women have the highest mortality from breast cancer -- regardless 
of breast cancer stage at diagnosis.1,3 As such, breast cancer remains a significant public health 
problem. 
Multiple molecular subtypes of breast cancer have been defined and characterized.4–8 
Hormone receptor positive (HR+) tumors are both estrogen receptor positive (ER+) and 
progesterone receptor positive (PR+).4 Alternatively, breast cancer tissues may overexpress the 
human epidermal receptor 2 protein (HER2+) or may lack ER, PR, and HER2 expression, in 
which case the tumor is classified as triple negative breast cancer (TNBC).4,6–8 Between 10-20% 
of all breast cancer diagnoses are triple-negative,4 and TNBC is more common among young 
black and Hispanic women than in young women of other racial and ethnic groups.5,7,9 TNBC is 
a particularly aggressive and challenging tumor type to treat since endocrine therapy or targeted 
treatment of HER2 cannot be pursued.4,5,7,10 Chemotherapy is currently the primary treatment for 
TNBC,5 but patients with TNBC still have an extremely poor prognosis7,9–13 and typically have 




honors thesis will investigate TNBC through use of the phenotypically similar E0771 cell line,14 
as this breast cancer subtype remains a pressing area of research due to the need for more 
targeted approaches to treatment. 
Obesity and Breast Cancer 
 Body mass index (BMI), in which body weight (in kilograms) is divided by height (in 
meters) squared, is the internationally accepted standard for obesity classification.15 A BMI 
greater than or equal to 30 is considered obese while severe obesity is classified as a BMI greater 
than or equal to 40.16 The prevalence of obesity, including severe obesity, is increasing steadily 
with recent estimates that 42.4% of American adults are obese.16 Obesity often induces 
metabolic dysregulation, resulting in elevated hormones, increased growth factors, and a state of 
chronic inflammation.17–20 As a result of associated perturbations throughout the body, obesity is 
a well-established risk factor for breast cancer.20–24 Relative to women who are normoweight, 
women who are obese have an increased risk of invasive breast cancer, distant metastases, and 
breast cancer-associated mortality.20,25,26 Further, breast cancer is often detected at a later stage in 
patients who are obese20,27–29 which likely contributes to the discrepancy in mortality between 
women who are normoweight and women who are obese.20 
Weight Loss Interventions for Obesity and Breast Cancer Outcomes 
Effective interventions are urgently needed to break the obesity-breast cancer link, and 
weight loss is a promising strategy.30–35 One common approach to weight loss is dietary calorie 
restriction. Calorie restriction regimens can either constitute a daily reduction in caloric intake or 
a more intermittent pattern.36 Daily or “chronic” calorie restriction (CCR) can range from a 15-




between days on which normal caloric intake is maintained and days on which there is a severe 
reduction in energy consumption.36 Motivation to develop the ICR regimen originated from 
studies suggesting that CCR is difficult for people to sustain for long periods of time and, in fact, 
greater adherence is often seen with ICR than with CCR.36,37 
CCR and ICR are likely equally effective at reducing body weight and fat mass,34,36,38 though 
there is some evidence that CCR may lead to greater weight loss.39 One randomized trial 
conducted by Harvie et al. compared the efficacy of both CCR and ICR interventions in women 
who were overweight.34 CCR was defined as a daily 25% caloric reduction from baseline energy 
needs while ICR involved a 75% calorie reduction on 2 consecutive days per week and no 
reduction the remaining 5 days of the week, thereby also equating to a weekly 25% reduction.34 
Ultimately, this study concluded that there was no significant difference in weight loss between 
the two types of calorie restriction: 64% of women in the ICR group and 55% of women in the 
CCR group lost at least 5% body weight.34  
Numerous studies have demonstrated that a variety of fasting paradigms have effectively 
slowed the growth of breast, colorectal, melanoma, neuroblastoma, and pancreatic tumors in both 
immunocompetent and immunocompromised animal models.33,40,41 Calorie restriction has also 
been associated with reduced cancer incidence and has been suggested as a tool for cancer 
prevention.33,40,42 Moreover, Harvie et al. noted improvements in breast cancer markers (e.g., 
reductions in serum leptin, leptin:adiponectin, dehydroepiandrosterone, and free androgen index; 
increases in sex hormone binding globulin) for both the CCR and ICR groups.34 As such, 
research investigating the physiological alterations induced by CCR and ICR may provide 




Bariatric surgery is another common approach to weight loss. This family of procedures 
includes vertical sleeve gastrectomy (VSG), Roux-en-Y gastric bypass (RYGB), laparoscopic 
adjustable gastric banding (LAGB), as well as other less common techniques. However, VSG 
and RYGB together account for more than 95% of all primary bariatric surgeries.43 The aim of 
VSG is to excise approximately 80% of the stomach while RYGB involves rerouting of the 
gastrointestinal tract.43 One year post-operatively, average body weight reduction ranges between 
23-27% for VSG and is approximately 29% for RYGB.30,44 However, recent estimates indicate 
that VSG is now performed three times more frequently than RYGB, likely due to the greater 
complexity of the RYGB procedure and the increased likelihood of more postoperative 
complications and nutritional challenges.43 Specifically, malnutrition and hyperinsulinemic 
hypoglycemia are both more prevalent in patients receiving RYGB than in patients undergoing 
VSG.43 However, nutrient deficiencies and dumping syndrome have been reported as long-term 
complications of both surgical procedures, and weight regain may occur in some patients 
following either procedure.45,46 
Similar to calorie restriction, bariatric surgery also reduces cancer risk, including breast 
cancer.30,47–51 Some evidence suggests that patients who undergo RYGB may have a lower risk 
of developing breast cancer than those receiving VSG or LAGB, but this study still concluded 
that bariatric surgery generally reduces breast cancer risk irrespective of procedure type.51 On the 
contrary, an association has been reported between biomarkers of colorectal cancer risk and 
RYGB, but not VSG.52 Schauer et al. found that weight loss following bariatric procedures, 
including VSG, RYGB, and LAGB, significantly reduced the risk of any cancer and this effect 
was increased with every additional 10% body weight loss.30 Further, another study found that 




cancer compared with matched participants with severe obesity who did not undergo surgery.31 
Similarly, over a 24 year follow-up period, Adams et al. found a 24% reduction in total cancer 
incidence and a 46% reduction in cancer mortality in patients with severe obesity receiving 
bariatric surgery compared with non-surgical participants.49 With respect to breast cancer 
specifically, current evidence suggests that bariatric surgery may reduce incidence.51,53,54 As 
such, investigating the physiological changes resulting from bariatric surgery and understanding 
how these changes impact cancer outcomes is warranted. 
Association of Weight Loss and Cancer Outcomes with Inflammatory, Hormonal, and 
Microbial Profiles 
Cytokines and Chemokines 
Obesity-induced adipose expansion is associated with increases in many proinflammatory 
cytokines and chemokines, including Interleukin(IL)-1β, IL-6, C-C motif chemokine 
ligand(CCL)2, CCL5, CXCL12, CXCL13, interferon(IFN)-γ, and tumor necrosis 
factor(TNF)α.17–19,55–57 While many proinflammatory cytokines and chemokines contribute to the 
obesity-cancer link, TNFα has been shown to activate Nuclear Factor(NF-)κB, a transcription 
factor involved in cancer pathogenesis, and IL-6 has been demonstrated to activate the Janus 
kinase/signal transducers and activators of transcription (JAK/STAT) pathway to promote cancer 
cell proliferation and survival, as well as angiogenesis.19,58 These cytokines thereby mediate 
tumor growth, providing a direct mechanistic link between obesity, inflammation, and 
cancer.19,20,56,58 Moreover, weight loss is known to decrease circulating levels of IL-6 and 
TNFα.19,20,56 As such, weight loss may blunt the adverse effects of these cytokines and 






Obesity is also positively associated with circulating leptin, PAI-1, insulin, and insulin-
like growth factor (IGF-)1 levels, and negatively associated with adiponectin.17,19 These obesity-
associated changes to levels of metaboendocrine hormones consequently influence breast tumor 
growth.28 In vitro, leptin promotes cell motility, invasiveness, and proliferation in a variety of 
cancer types, as well as increases production of proinflammatory cytokines.19,59,60 Adipocyte-
derived PAI-1 contributes to cancer cell invasiveness, as well as to metastasis; importantly, 
levels of this circulating hormone may serve as a prognostic indicator for breast cancer.19 
Moreover, there is evidence to support increased circulating IGF-1 as a risk factor for multiple 
cancers, attributable to its downstream activation of signaling pathways that support 
proinflammatory gene expression and thereby tumorigenesis.28,59 However, weight loss is known 
to improve hormonal profiles and thereby contribute to improved cancer outcomes.34,61 Harvie et 
al. revealed improvements in fasting insulin, leptin, the leptin:adiponectin ratio, and IGF binding 
proteins 1 and 2 resulting from both CCR and ICR interventions in women classified as 
overweight.34 Similarly, an association between reduced cancer risk and decreased circulating 
insulin and leptin levels following bariatric surgery has been reported.61 Thus, changes to 
circulating metaboendocrine hormones may mediate improved cancer outcomes following 
weight loss,61 illuminating the importance of evaluating these markers in the context of obesity 
and breast cancer studies. 
Gut Microbiota 
The gut microbiota is a living community of microbes that exist throughout the 
gastrointestinal tract.62 Community structure varies greatly on an individual basis and can be 




procedures.62–70 Obesity substantially alters gut microbial composition in both humans and 
animals71–75 and is associated with gut microbial dysbiosis.6,76 A high-fat diet may result in 
increased levels of gut microbiota from the Proteobacteria phylum that promote 
inflammation,63,77 and there is evidence that obesity-associated gut microbes harbor an increased 
ability to extract energy from the diet relative to lean-associated microbes.71 Moreover, multiple 
studies suggest that gut microbial communities may actually modulate weight loss following 
bariatric surgery.67,69,70 Graessler et al. reported a relationship between BMI, gut microbial 
composition, and inflammatory state66 while another study has similarly found decreased 
inflammatory markers to be associated with changes to the gut microbiota following weight loss 
surgery.69 Notably, in a case-control study, women with breast cancer were found to have altered 
gut microbiota composition relative to women without malignancy78 and low gut microbial 
diversity has been shown to be associated with breast cancer.6,78 Therefore, investigating the gut 
microbiota as a potential mediator in breast cancer progression is warranted. 
Comparative Effects of Dietary and Surgical Weight Loss on Breast Cancer Outcomes 
 In the parent study for this honors thesis, it was found that tumors from formerly obese 
mice receiving calorie restriction interventions, both CCR and ICR, were significantly smaller in 
size relative to tumors from mice who lost weight via VSG. While improved cancer outcomes 
following both dietary and surgical weight loss interventions are supported by the literature, 
studies directly comparing the physiological alterations induced by these approaches are 
limited.79 Through evaluating serum biomarkers and cecal microbiota, this honors thesis aims to 
delineate the differential impacts of calorie restriction and bariatric surgery on breast tumor 




interventions may provide valuable insight into mitigating the protumorigenic effects of obesity 




Goals and Hypothesis 
The purpose of this honors thesis is to elucidate how calorie restriction and vertical sleeve 
gastrectomy differentially alter plasma biomarkers and cecal microbial communities and to 
determine which of these changes are associated with improved tumor outcomes. We 
hypothesize that a greater reduction in obesity-associated serum hormones and proinflammatory 
cytokines and chemokines, as well as altered cecal microbial community composition, will be 
observed in the calorie restriction groups and will be associated with smaller final tumor mass. 
Aim 1. Determine which circulating plasma cytokines and chemokines are associated with 
decreased mammary tumor mass in mice fed chronic and intermittent calorie restriction 
diets compared with mice undergoing vertical sleeve gastrectomy. 
 Serum cytokines and chemokines were measured using the BIO-RAD Mouse Chemokine 
31-Plex Panel. One-way ANOVAs, a principal component analysis (PCA) plot, Spearman rank 
correlations, and multiple linear regression analyses were performed to determine differences 
among the intervention groups and to evaluate if individual cytokines/chemokines were 
associated with and/or independently predicted final tumor mass. 
Aim 2. Establish which circulating plasma metaboendocrine hormones are related to 
reduced mammary tumor burden in mice receiving calorie restriction interventions 
relative to mice undergoing vertical sleeve gastrectomy. 
 Serum metaboendocrine hormones were measured using multiple BIO-RAD and R&D 
Systems panels on the BIO-RAD MAGPIX instrument. One-way ANOVAs, a principal 




analyses were performed to determine differences among the intervention groups and to evaluate 
if individual hormones were associated with and/or independently predicted final tumor mass. 
Aim 3. Identify bacterial species in the cecal microbiome of mice fed chronic and 
intermittent calorie restriction diets that are associated with reduced mammary tumor size 
compared with mice receiving vertical sleeve gastrectomy. 
 DNA was isolated from cecal samples of all mice and the 16S rRNA gene was 
sequenced. Intra- and inter-group diversity was measured, differential abundance analyses were 
performed, and Spearman rank correlations were calculated to investigate differences among the 






Animal Husbandry and Diets 
The animal protocol for this study was approved by the University of North Carolina at 
Chapel Hill Institutional Animal Care and Use Committee, and the study was conducted in 
compliance with all guidelines and regulations. 8-week-old female C57BL/6NCrl mice (n = 89) 
were obtained from Charles River Laboratories, Inc. (Wilmington, MA) and body weight was 
measured weekly. Following a 1-week acclimation period, 20 mice were randomly assigned to 
maintain an ad libitum 10 kcal% fat control diet throughout the study (CON; n = 20; D12450J, 
Research Diets, Inc., New Brunswick, NJ). All other mice were placed on an ad libitum 60 
kcal% fat diet (D12492, Research Diets, Inc., New Brunswick, NJ) to promote diet-induced 
obesity (DIO). After 15 weeks on diet, all mice were singly housed and randomized to receive 
either: a) sham surgery and continuation of the 10 kcal% fat diet (CON; n=20); b) sham surgery 
and continuation of the 60 kcal% fat diet (DIO; n=18); c) sham surgery with switch to a 30% 
chronic calorie restriction diet (CCR; n=16; D15032801, Research Diets, Inc., New Brunswick, 
NJ); d) sham surgery with switch to an intermittent calorie restriction diet (ICR; n=19); or e) 
vertical sleeve gastrectomy with switch to 10 kcal% fat control diet (VSG; n=16; D12450J, 
Research Diets, Inc., New Brunswick, NJ). Mice on the ICR diet received a 14% calorie 
reduction 5 days per week (D15032803, Research Diets, Inc., New Brunswick, NJ) and a 70% 
calorie reduction on 2 non-consecutive days each week (D15032804, Research Diets, Inc., New 
Brunswick, NJ) equating to a weekly average of 30% calorie restriction. 30% calorie restriction 
for both CCR and ICR mice was calculated using the average food consumption of CON mice 





Bariatric and Sham Surgeries 
Trained animal surgeons performed either VSG or sham surgeries on all mice. Prior to 
surgeries, all mice were individually housed and fasted overnight for 14-16 hours. At time of 
surgery, each mouse was subcutaneously injected with buprenorphine (0.05-0.1 mg/kg), 
carprofen (5 mg/kg), gentamicin (8 mg/kg), enrofloxacin (10 mg/kg), and 1-2% (w/v) isoflurane 
in O2 was continuously administered via nosecone to ensure complete anaesthetization. Vertical 
sleeve gastrectomy surgeries involved making a midline abdominal incision and resecting ~80% 
of the greater curvature of the stomach. For sham surgeries, surgeons made a midline abdominal 
incision but did not manipulate or ligate the stomach or intestines. During the 7-day recovery 
period following surgery, all mice were monitored twice daily by measuring body weight and 
food consumption and assessing hydration status. Additionally, mice received 1.0 mL 
subcutaneous injections of warm sterile saline once daily for 1-3 days, as well as subcutaneous 
injections of buprenorphine (0.05-0.1 mg/kg) twice daily for 3 days; carprofen (5 mg/kg) and 
gentamicin (8 mg/kg) once daily for 3 days; and enrofloxacin (10 mg/kg) once daily for 7 days. 
Heating pads and hydrogel were provided as necessary. Following a full recovery, calorie 
restriction interventions began two weeks after surgeries. 
Serum Cytokines/Chemokines and Hormones 
Prior to E0771 cell injections, 100 μL of blood from animals fasted for 6 hours was 
collected via submandibular bleed. Blood sat for 30 minutes at room temperature prior to 
centrifugation at 10,000 x g for 10 minutes at 4°C. Serum was collected and stored at -80°C until 
Luminex assays were run. Circulating serum cytokines, chemokines, and hormones were 
analyzed using a Bio-Plex Pro Mouse Chemokine 31-Plex Panel (BIO-RAD, Hercules, CA) with 




with a dilution factor of 4, a Bio-Plex Pro Mouse Diabetes Adiponectin Assay (BIO-RAD, 
Hercules, CA) with a dilution factor of 1600, and a Mouse Magnetic Luminex IGF-1 Assay 
(R&D Systems, Minneapolis, MN) with a dilution factor of 50 on a Bio-Plex MAGPIX 
instrument (BIO-RAD, Hercules, CA) according to manufacturer’s instructions. 
Cell Injections and Tumor Growth Monitoring 
E0771 cells were purchased from CH3 BioSystems (Amherst, NY). At study week 27, 
3.5x104 E0771 cells suspended in 50 μL sterile PBS were orthotopically injected into the fourth 
mammary fat pad of all mice. Mice were then monitored daily and in vivo tumor growth was 
measured twice weekly using skin fold digital calipers. Any given mouse was euthanized for 
tissue collection if tumor size reached 1.5 cm in either direction. All mice were euthanized when 
50% of tumors from DIO mice -- the group in which tumor growth progressed most quickly -- 
were at least 1 cm in either direction which occurred at week 31 of the study. Ex vivo tumor 
volume was calculated using the formula (0.5R1)(R22) where R1 is the maximum dimension and 
R2 is the minimum dimension. At time of tissue harvest, tumors were excised and weighed with a 
digital scale. 
Cecal 16S rRNA Gene Sequencing and Analysis 
Cecal contents from 10 mice per group centered around the respective group’s median 
tumor mass were chosen for 16S rRNA gene sequencing. The Microbiome Core at the UNC 
School of Medicine (Chapel Hill, NC) extracted the cecal DNA, amplified the 16S rRNA gene 
using the polymerase chain reaction (PCR), barcoded the resulting amplicons, and sequenced the 




Paired-end sequences were demultiplexed and processed using Quantitative Insights Into 
Microbial Ecology 2 (QIIME2) version 2020.11.80 Divisive Amplicon Denoising Algorithm 
(DADA2) was used to correct sequencing-based amplicon errors and assign sequence variants 
(SVs) at a 100% identity threshold.81 Forward and reverse primers were truncated at 222 base 
pairs. SVs with less than 0.01% frequency were filtered out, and the minimum sequencing depth 
for sample retention was set to 2000 reads. Of the 49 samples that remained after filtering, the 
final number of unique SVs was 253 and the final number of total reads was 4,013,080. 
α-diversity was assessed by both Shannon index and the number of unique SVs per 
sample. β-diversity was assessed using Bray-Curtis dissimilarity indices. Bray-Curtis principal 
coordinate analysis (PCoA) plots were generated and dissimilarity indices were calculated using 
the vegan R package version 2.5-7. Spearman rank correlations and differential abundance 
analyses were performed using the MicrobiomeExplorer R package version 1.0.4.82 
Statistical Analysis 
GraphPad Prism version 9.0.0 or R was used for all statistical analyses and adjusted p-
values less than 0.05 were considered statistically significant.  
For circulating serum cytokine/chemokine and hormone analyses, a one-way ANOVA 
was performed followed by a Tukey post-hoc test. For each multiple linear regression analysis, 
least squares regression models were fitted -- with and without two-way interactions. The 
simpler, main effects only model, was used unless the sum of squares F test p-value was less 
than 0.05. To adjust for multiple hypothesis testing, q-values (i.e., adjusted p-values) were 
calculated using the Benjamini, Krieger and Yekutieli two-stage linear step-up procedure with a 




to create PCA plots, as well as to calculate z scores from which heat maps for circulating serum 
cytokines/chemokines and hormones were created using GraphPad Prism software. 
For 16S rRNA gene sequencing analysis, statistically significant differences between 
groups for Shannon index and the number of observed SVs were determined using a one-way 
ANOVA with a Tukey post-hoc test. A PERMANOVA test (vegan R package version 2.5-7) was 
used to determine differences in cecal microbial composition between groups. For the 
differential abundance analysis, DESeq2 was used to normalize the data and generate p-values 
for pairwise comparisons.83 To adjust for multiple hypothesis testing, q-values were calculated 
using the Benjamini, Krieger and Yekutieli two-stage linear step-up procedure with a FDR of 
5%. Spearman rank correlation analyses of diversity measures with parameters of interest were 





Calorie restriction significantly reduces the pro-tumorigenic effects of obesity 
The motivation for this honors thesis emerged from an initial study seeking to test if surgical 
and/or dietary weight loss interventions could effectively reduce tumor growth in a mouse model 
of breast cancer. For the first 15 weeks, female C57BL/6NCrl mice from Charles River 
Laboratories were either maintained on a 10 kcal% fat diet (CON; n=20) or placed on a 60 kcal% 
fat diet to promote diet-induced obesity (DIO; n=69) (Figure 1). Mice were then randomized to 
receive either: a) sham surgery and continuation of the 10 kcal% fat diet (CON; n=20); b) sham 
surgery and continuation of the 60 kcal% fat diet (DIO; n=18); c) sham surgery with switch to a 
30% chronic calorie restriction diet (CCR; n=16); d) sham surgery with switch to an intermittent 
calorie restriction diet (ICR; n=19); or e) vertical sleeve gastrectomy with switch from 60 kcal% 
fat diet to 10 kcal% fat diet (VSG; n=16) (Figure 1). Mice on the ICR diet had a 14% calorie 
reduction 5 days per week and then a 70% calorie reduction on 2 non-consecutive days each 
week, equating to a weekly average of 30% calorie restriction. Both CCR and ICR diets were 
calculated using CON mice intake data as a reference point and were formulated by 
ResearchDiets, Inc. to ensure adequate micronutrient intake. 11 weeks following surgeries, 
3.5x104 E0771 cells were orthotopically injected into the fourth mammary fat pad. All mice were 
euthanized for tissue harvest when 50% of tumors from DIO mice were at least 1 cm in either 





Figure 1. Study design. 
Body weights were not initially different across groups (Supplemental Figure 1A). As 
expected, mice transiently lost weight following sham and bariatric surgeries. At the end of the 
31-week study, DIO mice weighed more than all other groups (p < 0.0001). Body weights 
between CON and VSG groups were not different, while CCR and ICR mice weighed 
significantly less than all other groups (p < 0.0001) (Supplemental Figure 1A). 
Food intake monitoring began immediately post-surgery. After two weeks, CCR and ICR 
mice began respective energy intake reductions equating to a weekly calorie restriction of 30%. 
At the end of the study, food consumption was not significantly different between CON, DIO, 
and VSG mice, while CCR and ICR mice consumed less food due to their calorically restrictive 




DIO mice consumed the greatest amount of calories each week compared with all other groups 
resulting from their energy-dense 60 kcal% fat diet (p < 0.0001) (Supplemental Figure 1C). 
At the end of the study, tumor mass and volume were significantly greater in DIO mice 
relative to CON (p < 0.05), CCR (p < 0.0001) and ICR (p < 0.0001) mice (Supplemental 
Figures 1D-E). Tumor mass in VSG mice was not significantly different from either CON or 
DIO mice. Both CCR and ICR interventions resulted in significantly reduced tumor mass (p < 
0.05) and volume (p < 0.05) compared with all other groups (Supplemental Figures 1D-E). 
These data provide evidence that calorie restriction reduces mammary tumor mass to a 
greater extent than bariatric surgery. Therefore, we were interested in further investigating 
specific factors—namely cytokines, chemokines, metaboendocrine hormones, and intestinal 
microbes—that have been shown to play an important role in promoting, or mitigating, tumor 
growth. We hypothesize that these biological factors may contribute to the differential tumor 
outcomes observed between calorie restriction (dietary) and vertical sleeve gastrectomy 
(surgical) weight loss interventions. 
All weight loss interventions resulted in reduced levels of multiple cytokines and 
chemokines compared with DIO mice while CXCL13 was the only chemokine lowered in 
calorie restriction mice relative to VSG mice 
To assess systemic differences in the tumor naïve environment resulting from a dietary 
(CCR, ICR) or surgical (VSG) weight loss intervention, we first measured a panel of circulating 
serum cytokines and chemokines that was collected via submandibular bleed prior to E0771 cell 
injections. Dietary or surgical weight loss reduced a number of circulating cytokines and 
chemokines that are classically induced by obesity, including IL-2, IL-6, and TNFα, as well as 
CCL27 (Figures 2A-E; Table 1). Compared with VSG mice, only CXCL13 was significantly 




ICR, but not CCR, mice, CXCL12 (p < 0.001) and CXCL17 (p < 0.01) were both significantly 
elevated relative to VSG mice (Figures 2G-H). Circulating CXCL12 was also significantly 
elevated in ICR versus CON mice (p < 0.01) but was reduced in VSG mice relative to DIO mice 
(p < 0.05) (Figure 2G). Similarly, CXCL17 was elevated in the serum of ICR versus CON mice 
(p < 0.01) (Figure 2H).  
To better visualize the variance in serum cytokine and chemokine profiles amongst the 
five groups, a principal component analysis (PCA) plot was created. However, the PCA plot 
revealed that the groups could not be discriminated based on cytokine and chemokine profile 
(Figure 2I). Finally, we performed multiple linear regression analyses to determine if any serum 
cytokines or chemokines predicted tumor mass independent of intervention group. However, 
none of the 30 cytokines or chemokines analyzed were found to independently predict tumor 
mass (Table 2). Taken together, these data suggest that circulating cytokines and chemokines are 









Figure 2. Circulating serum cytokines and chemokines prior to E0771 cell injections. (A) Heat 
map displaying average z scores of serum concentrations of 30 cytokines and chemokines. (B) 
IL-2 serum concentration. Mean ± SEM. (C) IL-6 serum concentration. Mean ± SEM. (D) TNFα 
serum concentration. Mean ± SEM. (E) CCL27 serum concentration. Mean ± SEM. (F) CXCL13 
serum concentration. Mean ± SEM. (G) CXCL12 serum concentration. Mean ± SEM. (H) 
CXCL17 serum concentration. Mean ± SEM. (I) Principal component analysis plot of 30 
cytokines and chemokines. 
Statistical analysis was conducted using a one-way ANOVA with Tukey post-hoc test. 
*p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; n= 14-20/group. 
 
Table 1. Circulating serum cytokine and chemokine concentrations significance table.  













CON DIO CCR ICR VSG
TNFα a,b a a,b a,b b
IFNγ a a a a a
GM-CSF a,b a a,b a,b b
IL-1β a b a,b a,b b
IL-2 a,b a b b a,b
IL-4 a a a a a
IL-6 a,b a b b a,b
IL-10 a a a a a
CCL1 a a a a a
CCL2 a a a a a
CCL3 a a a a a
CCL4 a,b a a,b a,b b
CCL5 a a a a a
CCL7 a a a a a
CCL11 a a a a a
CCL12 a a a a a
CCL19 a a a a a
CCL20 a a a a a
CCL22 a a a a a
CCL24 a a a a a
CCL27 a,b a b b a,b
CX3C a a a a a
CXCL1 a a a a a
CXCL5 a a a a a
CXCL10 a a a a a
CXCL11 a a a a a
CXCL12 a,c a,b a,b,c b c
CXCL13 a,b a,b b b a
CXCL16 a a,b b b b




Table 2. Multiple linear regression analyses of 30 circulating serum cytokines and chemokines. 
 
  








variables  Lower Upper 
Variables        
TNFα No 1.53e-4 -8.32e-5 3.89e-4 0.200 0.967 0.113 
IFNγ No 5.98e-5 -4.08e-4 5.28e-4 0.799 0.981 0.075 
GM-CSF No 0.004 -0.004 0.013 0.303 0.967 0.113 
IL-1β No 6.57e-5 -1.85e-4 3.16e-4 0.603 0.981 0.142 
IL-2 No 5.91e-4 -6.29e-4 0.001 0.337 0.967 0.161 
IL-4 No 5.39e-4 -8.79e-4 0.001 0.451 0.981 0.090 
IL-6 No 2.10e-4 -8.98e-4 0.001 0.706 0.981 0.129 
IL-10 No -1.13e-5 -8.59e-5 6.33e-5 0.764 0.981 0.077 
CCL1 No 7.11e-4 -0.001 0.003 0.553 0.981 0.108 
CCL2 No 4.25e-5 -1.76e-4 2.61e-4 0.700 0.981 0.115 
CCL3 No -5.30e-5 -0.004 0.004 0.979 1.000 0.060 
CCL4 No 5.01e-4 -4.25e-4 0.001 0.284 0.967 0.112 
CCL5 No 8.70e-4 -7.40e-4 0.002 0.284 0.967 0.058 
CCL7 No 5.90e-5 -3.84e-4 5.02e-4 0.791 0.981 0.069 
CCL11 No -4.54e-5 -2.25e-4 1.34e-4 0.616 0.981 0.071 
CCL12 No 0.002 -1.96e-4 0.005 0.066 0.967 0.052 
CCL19 No -2.58e-6 -9.92e-5 9.41e-5 0.957 1.000 0.099 
CCL20 No 0.001 -0.001 0.003 0.315 0.967 0.069 
CCL22 No -1.13e-4 -8.90e-4 6.64e-4 0.772 0.981 0.076 
CCL24 Yes -4.04e-5 -1.09e-4 2.89e-5 0.248 0.967 0.735 
CCL27 No 1.20e-5 -2.57e-5 4.97e-5 0.528 0.981 0.200 
CX3C No 5.23e-6 -7.33e-4 7.44e-4 0.988 1.000 0.099 
CXCL1 No 7.35e-5 -5.83e-4 7.30e-4 0.824 0.981 0.098 
CXCL5 No -8.14e-6 -1.67e-5 3.99e-7 0.061 0.967 0.069 
CXCL10 No 1.91e-5 -1.91e-5 5.73e-5 0.322 0.967 0.052 
CXCL11 No 2.41e-5 -1.97e-5 6.79e-5 0.277 0.967 0.081 
CXCL12 No -9.64e-6 -5.69e-5 3.76e-5 0.685 0.981 0.188 
CXCL13 No 7.06e-6 -1.77e-5 3.19e-5 0.572 0.981 0.113 
CXCL16 No 2.684e-4 -3.27e-4 8.64e-4 0.372 0.977 0.215 





Calorie restriction results in significantly lower circulating PAI-1 compared with bariatric 
surgery 
Given that circulating metaboendocrine hormones are also impacted by weight loss, we 
wanted to next assess if these may be playing a significant role in the increased reduction in 
tumor size resulting from dietary versus surgical intervention. Using the same tumor naïve 
serum, we assessed the possible contribution of 10 selected hormones on mammary tumor 
outcomes. 
As anticipated, circulating leptin and resistin were both reduced in dietary (CCR, ICR) and 
surgical (VSG) weight loss groups compared with DIO mice (Figure 3A; Table 3). 
Additionally, PAI-1 was significantly reduced in serum from CCR mice (p < 0.05) and ICR mice 
(p < 0.05) relative to DIO mice but elevated in VSG mice relative to all other groups (p < 0.001) 
except DIO mice (Figure 3B; Table 3). Moreover, it was found that the leptin:adiponectin ratio 
was significantly reduced across all weight loss interventions compared with DIO mice (p < 
0.0001 versus CCR, ICR, and VSG mice) (Figure 3C; Table 3). However, adiponectin alone 
was found to be significantly higher in serum from CCR mice relative to all other groups (p < 
0.01 versus CON, DIO, and VSG mice; p < 0.05 versus ICR mice) (Table 3). IGF-1 was 
significantly reduced in serum from CCR and ICR mice relative to both CON mice (p < 0.0001) 
and DIO mice (p < 0.001). Serum IGF-1 was also reduced in VSG mice versus CON mice (p < 
0.01) but not versus DIO mice (Figure 3D). 
A PCA plot was created to visualize the collective variance amongst the five groups with 
respect to metaboendocrine hormone profiles. However, similarly to the plot of circulating 
cytokines and chemokines, it was again demonstrated that distinct metaboendocrine hormone 




Figure 3. Circulating serum metaboendocrine hormones prior to E0771 cell injections. (A) Heat 
map displaying average z scores of serum concentrations of 10 hormones. (B) PAI-1 serum 
concentration. Mean ± SEM. (C) Leptin:adiponectin serum concentration. Mean ± SEM. (D) 
IGF-1 serum concentration ratio. Mean ± SEM. (E) Principal component analysis plot of 10 
hormones (adiponectin, ghrelin, GIP, GLP-1, glucagon, IGF-1, insulin, leptin, PAI-1, resistin). 
Statistical analysis was conducted using a one-way ANOVA with Tukey post-hoc test.  




Table 3. Circulating serum metaboendocrine hormone concentrations significance table. 











PAI-1 and body weight loss are significant predictors of final tumor mass 
We next ran multiple linear regression analyses to determine if any serum hormones 
predicted tumor mass independent of intervention group. Of all 10 hormones tested, these 
analyses revealed that serum PAI-1 (q < 0.01) independently predicted tumor mass (Table 4). In 
addition to PAI-1, IGF-1 was also found to be a significant predictor of final tumor mass (p < 
0.05) but did not remain significant after adjusting for multiple hypothesis testing (Table 4). 
Table 4. Multiple linear regression analyses of 10 circulating serum metaboendocrine hormones. 
 
CON DIO CCR ICR VSG
Adiponectin a a b a a
Ghrelin a,b b a,b a b
GIP a a a a a
GLP-1 a a a a a
Glucagon a a a a a
IGF-1 a a,b c c b,c
Insulin a a a a a
Leptin a b a,c c a,c
Leptin:Adiponectin a b a a a
PAI-1 a,b b,c a a c




To recognize the potentially important contribution of body weight loss on tumor 
growth—particularly given the significantly greater weight loss achieved by both dietary (CCR, 
ICR) interventions relative to the surgical (VSG) intervention—we ran a separate multiple linear 
regression analysis to assess whether body weight independently predicted tumor mass. Upon 
running this model, body weight loss was indeed found to be a significant predictor of final 
tumor mass (p < 0.05) (Table 5). Overall, the superior reversal of the obesity-exacerbated tumor 
growth achieved by calorie restriction interventions may be partially attributable to changes in 
circulating PAI-1 levels and/or to substantial body weight loss. 





Cecal microbial composition is distinct across all intervention groups 
Gut microbial communities may be an additional biological factor that contribute to 
tumor outcomes.84,85 Therefore, to evaluate the cecal microbial communities within (α-diversity) 
and across (β-diversity) the intervention groups, we next performed 16S rRNA gene sequencing 
and analyzed the data using QIIME2.80 A PCoA plot using Bray Curtis dissimilarity indices 
demonstrated that cecal microbes from VSG mice form a cluster separate from other intervention 
groups – particularly CON, DIO, and ICR mice – along PC1, which accounts for 23% of the 
variation amongst the samples (Figure 4A). A PERMANOVA test based on the Bray Curtis 
index values revealed that the cecal microbiotas were significantly different across all 









variables  Lower Upper 
Variables       





intervention groups (q < 0.05). Overall, this suggests that both dietary and surgical weight loss 
interventions drive changes in cecal microbial community composition. 
α-diversity is negatively correlated with final tumor mass 
Since all intervention groups diverged on the basis of β-diversity, we next analyzed α-
diversity to gain insight into whether there were also differences in microbial diversity within 
intervention groups. Using the Shannon index, α-diversity was not significantly different 
between intervention groups (Figure 4B). We also analyzed α-diversity by assessing the number 
of unique SVs accounted for in each group. Interestingly, cecal samples from VSG mice had 
significantly fewer observed SVs compared with cecal samples from CON (p < 0.001), DIO (p < 
0.01), and ICR (p < 0.0001) mice (Figure 4C). Moreover, cecal samples from ICR mice were 
found to have an increased number of SVs compared with samples from CCR mice (p < 0.05) 
(Figure 4C). 
To test whether α-diversity was related to other biologically relevant measures that we 
found to differ between dietary and surgical weight loss groups, we ran Spearman correlation 
analyses. These analyses included gross body weight loss, final tumor mass, and circulating 
CXCL12, CXCL13, CXCL17, IGF-1, and PAI-1 levels. However, none of these measures were 
significantly correlated with Shannon α-diversity (Figure 4D). These specific chemokines, 
hormones, and gross body weight loss were also determined to not be correlated with the number 
of observed SVs. (Figure 4E). However, final tumor mass was significantly negatively 
correlated with the number of observed SVs (p < 0.05) (Figure 4E). This finding suggests that 
increased cecal α-diversity may be a contributing factor to the reduced tumor mass observed in 




Dietary versus surgical weight loss interventions result in significantly differentially 
abundant genera 
Finally, to better understand the specific changes in cecal microbiotas resulting from 
dietary and surgical weight loss interventions, a differential abundance analysis was performed 
in which the three intervention groups were directly compared. After adjusting for multiple 
hypothesis testing, 7 genera were found to be differentially abundant between both CCR and ICR 
mice versus VSG mice: Acetatifactor (q < 0.0001), Akkermansia (q < 0.05), Anaerotruncus (q < 
0.0001), Butyricimonas (q < 0.0001), Coprococcus 3 (q < 0.05), Oscillibacter (q < 0.0001), and 
Romboutsia (q < 0.0001) (Table 6). Notably, Spearman correlation analyses revealed 5 of these 
7 genera to be significantly correlated with final tumor mass, including Akkermansia, 
Anaerotruncus, Butyricimonas, Oscillibacter, and Romboutsia (Figure 4F). These data suggest 
that multiple genera are associated with these different weight loss interventions, as well as with 









Figure 4. Measures of cecal microbial diversity and correlations with biomarkers of interest. (A) 
Principal coordinate analysis plot of Bray-Curtis indices. (B) Shannon indices α-diversity. One-
way ANOVA with Tukey post-hoc test. (C) Unique sequence variants α-diversity. One-way 
ANOVA with Tukey post-hoc test. (D) Shannon index α-diversity Spearman rank correlations 
with biomarkers and parameters of interest. (E) Observed SVs α-diversity Spearman rank 
correlations with biomarkers and parameters of interest. (F) Spearman rank correlations of final 
tumor mass with differentially abundant genera between dietary versus surgical weight loss 
groups. 












Genera p_VSG vs CCR q_VSG vs CCR p_VSG vs ICR q_VSG vs ICR p_CCR vs ICR q_CCR vs ICR
Acetatifactor 0.000 0.000 0.000 0.000 0.858 0.801
Akkermansia 0.008 0.028 0.001 0.004 0.185 0.328
Anaerotruncus 0.000 0.000 0.000 0.000 0.859 0.801
Butyricimonas 0.000 0.000 0.000 0.000 NA
Coprococcus 3 0.012 0.040 0.001 0.004 0.636 0.695
Oscillibacter 0.000 0.000 0.000 0.000 0.487 0.589
Romboutsia 0.000 0.000 0.000 0.000 0.169 0.321
[Clostridium] innocuum group 0.884 0.806 0.000 0.000 0.000 0.000
[Eubacterium] brachy group 0.807 0.779 0.883 0.806 0.590 0.661
[Eubacterium] coprostanoligenes group 0.810 0.779 0.099 0.214 0.644 0.699
[Eubacterium] fissicatena group 0.775 0.774 0.013 0.042 0.483 0.588
[Eubacterium] nodatum group 0.122 0.250 0.275 0.422 0.357 0.504
[Eubacterium] xylanophilum group 0.215 0.361 0.000 0.000 0.581 0.661
A2 0.677 0.714 0.699 0.729 0.907 0.806
Alistipes 0.930 0.806 0.680 0.714 0.455 0.574
Anaerostipes 0.817 0.781 0.000 0.000 0.049 0.133
Bacteroides 0.008 0.028 0.077 0.183 0.732 0.754
Bifidobacterium 0.504 0.605 0.000 0.000 0.000 0.000
Bilophila 1.000 0.806 NA 1.000 0.806
Blautia 0.762 0.770 0.416 0.547 0.374 0.512
Candidatus Soleaferrea 0.739 0.756 0.178 0.323 0.086 0.192
Christensenellaceae R-7 group 0.965 0.806 0.029 0.084 0.026 0.077
Clostridioides 0.001 0.004 0.962 0.806 0.059 0.147
Clostridium sensu stricto 1 0.085 0.192 0.000 0.000 0.105 0.221
Clostridium sensu stricto 13 0.375 0.512 0.204 0.353 0.787 0.778
Clostridium sensu stricto 2 0.384 0.519 0.339 0.496 1.000 0.806
Corynebacterium 1 0.547 0.637 0.535 0.628 1.000 0.806
Defluviitaleaceae UCG-011 1.000 0.806 NA 1.000 0.806
Enterococcus 0.850 0.801 0.007 0.025 0.055 0.142
Enterorhabdus 0.967 0.806 1.000 0.806 0.732 0.754
Epulopiscium 0.479 0.588 0.350 0.504 0.792 0.778
Erysipelatoclostridium 0.314 0.464 0.356 0.504 0.018 0.056
Escherichia-Shigella 0.020 0.061 0.016 0.051 0.776 0.774
Faecalibaculum 0.051 0.136 0.535 0.628 0.000 0.000
Family XIII AD3011 group 1.000 0.806 0.000 0.000 0.833 0.791
Flavonifractor 0.891 0.806 0.003 0.011 0.002 0.008
GCA-900066575 0.049 0.133 0.001 0.004 0.680 0.714
Harryflintia 0.411 0.547 0.001 0.004 0.522 0.622
Hungatella 0.000 0.000 0.282 0.429 0.000 0.000
Hydrogenoanaerobacterium NA NA NA
Intestinimonas 0.366 0.508 0.021 0.063 0.418 0.547
Lachnoclostridium 0.676 0.714 0.000 0.000 0.000 0.000
Lachnospiraceae NK4A136 group 0.585 0.661 0.556 0.640 0.399 0.535
Lachnospiraceae UCG-004 0.147 0.293 0.000 0.000 0.799 0.778
Lachnospiraceae UCG-006 0.088 0.192 0.155 0.302 0.085 0.192
Lactobacillus 0.354 0.504 0.980 0.806 0.053 0.139
Lactococcus 0.557 0.640 0.363 0.508 0.946 0.806
Marvinbryantia 0.229 0.377 0.000 0.000 0.473 0.585
Parabacteroides 0.242 0.394 0.958 0.806 0.199 0.349
Parasutterella 0.167 0.321 0.000 0.000 0.000 0.000
Pygmaiobacter 1.000 0.806 1.000 0.806 NA
Robinsoniella 0.272 0.422 0.114 0.236 0.592 0.661
Roseburia 1.000 0.806 0.000 0.000 0.185 0.328
Ruminiclostridium 0.206 0.353 0.000 0.000 0.087 0.192
Ruminiclostridium 5 0.998 0.806 0.073 0.177 0.002 0.008
Ruminiclostridium 9 0.461 0.575 0.596 0.661 0.225 0.374
Ruminococcaceae NK4A214 group NA 1.000 0.806 1.000 0.806
Ruminococcaceae UCG-004 0.079 0.185 0.000 0.000 0.798 0.778
Ruminococcaceae UCG-010 0.250 0.399 0.000 0.000 0.439 0.565
Ruminococcaceae UCG-014 0.273 0.422 0.208 0.353 0.250 0.399
Ruminococcus 2 0.103 0.219 0.173 0.321 0.863 0.801
Staphylococcus 0.177 0.323 0.000 0.000 0.457 0.574
Streptococcus NA 0.432 0.561 0.309 0.461
Turicibacter 0.144 0.291 0.001 0.004 0.056 0.142
Tyzzerella 0.173 0.321 0.036 0.103 0.662 0.714








Supplemental Figure 1. Parent study data including body weight, food consumption, final 
tumor mass, and tumor growth. (A) Body weights across study. Mean ± SD. (B) Post-surgery 
weekly food intake in grams/mouse. Mean ± SD. (C) Weekly food intake in kcal/mouse for 
study week 30. Mean ± SD. (D) Final tumor mass. Mean ± SD. (E) Tumor volume following 
orthotopic injections of E0771 cells. Mean ± SD. 
Statistical analysis was conducted using a one-way ANOVA with Tukey post-hoc test. 
*p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; n=14-20/group. 






Obesity burdens more than 40% of American adults and is a well-established risk factor for 
breast cancer.16,20–24 Therefore, interventions to effectively reverse the protumorigenic effects of 
obesity have the potential to be incredibly impactful. The motivation for this honors thesis 
emerged from an initial study seeking to test if dietary and/or surgical weight loss interventions 
could effectively reduce tumor growth in a murine model of breast cancer. At the end of the 
parent study, DIO mice weighed the heaviest, consumed the most calories, and presented with 
significantly larger tumors than all other groups except VSG mice (Supplemental Figure 1). 
Additionally, tumors from VSG mice were significantly larger than tumors from CCR and ICR 
mice (Supplemental Figure 1) despite evidence in the literature that both dietary and surgical 
weight loss interventions may improve cancer outcomes.30,49,79 As such, this parent study 
provided a novel opportunity to understand how chronic calorie restriction, intermittent calorie 
restriction, and vertical sleeve gastrectomy differentially impact metabolic, inflammatory, and 
cecal microbial profiles to ultimately influence breast tumor outcomes. 
In our current study, we found that gross body weight loss was a significant independent 
predictor of final tumor mass (Table 5). Much of the literature is consistent with the idea that 
weight loss is largely responsible for metabolic improvements following either dietary or 
surgical intervention.30,49,79 In a study involving patients with obesity and type 2 diabetes 
mellitus who either underwent RYGB or who lost equivalent weight through dietary 
modification, it was found that the observed metabolic improvements were a function of the 
weight loss itself rather than attributable to the method of intervention.79 Another clinical study 
found a 24% reduction in cancer incidence and a 46% reduction in cancer mortality in patients 




not undergo surgery.49 The researchers concluded that these outcomes were most likely due to 
the weight loss and remarked that weight loss should therefore be recommended to reduce cancer 
risk.49 Interestingly, a retrospective matched cohort study reported that percent weight loss one 
year post-bariatric surgery was significantly correlated with reduced cancer incidence in adjusted 
models, but that bariatric surgery did not independently predict cancer incidence.30 A limitation 
of our study is that the amount of body weight loss was not equivalent among the three 
intervention groups; mice in dietary intervention groups (CCR, ICR) lost significantly more body 
weight than the surgical intervention group (VSG) by the end of the study (Supplemental 
Figure 1). We are therefore unable to conclude in this current study if the improved anticancer 
effects of calorie restriction relative to bariatric surgery were due solely to gross body weight 
loss or to other physiological alterations in serum biomarkers or cecal microbial profiles. 
Weight loss via both dietary and surgical intervention modulated a number of circulating 
cytokines and chemokines relative to DIO mice (Figure 2A). While no serum cytokines or 
chemokines were individually found to predict final tumor mass (Table 2), the chemokine 
CXCL13 emerged as a biomarker of interest due to its elevated concentration in serum from 
VSG mice relative to both CCR and ICR mice (Figure 2F). CXCL13 is widely considered to 
contribute to tumor growth and metastasis, as well as influence cancer cell proliferation, 
migration, and invasion.86–89 Overexpression of CXCL13 in cancer tissues and elevated levels in 
serum in women with breast tumors has been consistently reported, as well as postulated as a 
possible diagnostic marker for breast cancer.87–90 As a result, CXCL13 inhibition has been 
investigated as a possible therapeutic approach to breast cancer treatment.91,92 
Similar to circulating cytokines and chemokines, many hormones including leptin as well as 




surgical weight loss interventions relative to DIO mice (Figures 3A-D). Such improvements to 
metabolic profiles are commonly seen with weight loss and have the potential to influence cancer 
outcomes.28,61,93 In our study, serum PAI-1 levels were found to independently predict final 
tumor mass (Table 4). This finding is especially interesting given that circulating PAI-1 levels 
were significantly reduced in serum from both calorie restriction groups but elevated in serum 
from VSG mice (Figure 3B). In support of our findings, PAI-1 has been reported to be highly 
expressed in various tumor types including breast, stomach, head and neck, esophageal, 
thymoma, bladder urothelial, and testicular.94,95 PAI-1 has also been reported to be elevated in 
plasma from women with breast cancer relative to women who are healthy96,97 and has been 
established as a poor prognostic indicator, particularly for breast tumors.19,94,97,98 
Mechanistically, PAI-1 has been reported to contribute to cancer cell migration, metastasis, and 
angiogenesis.94 There is evidence that PAI-1 activates the phosphatidylinositol 3-phosphate 
kinase (P13K)/Akt cell survival pathway98 as well as the intracellular enzyme procollagen-lysine, 
2-oxoglutarate 5-dioxygenase (PLOD)2 in cancer-associated adipocytes.99 PLOD2 plays a 
prominent role in collagen biogenesis which may contribute to breast cancer cell migration.99 
Perhaps not surprisingly, many PAI-1 inhibitors are currently under evaluation for use in cancer 
therapy.94 Taken together, the serum markers CXCL13 and PAI-1– either alone or in 
combination – may provide insight as to why calorie restriction interventions had increased 
anticancer effects relative to bariatric surgery. 
Moreover, distinct cecal microbial composition was observed in all diet groups (Figure 4A). 
Interestingly, the number of observed SVs, but not the Shannon index, was reduced in cecal 
samples from VSG mice compared with ICR mice (Figures 4B-C). This may indicate that 




species present, but does not alter community uniformity. The number of observed SVs was also 
negatively correlated with final tumor mass (Figure 4E), suggesting that a greater number of 
bacterial species present in this community, but not necessarily an even distribution of this 
community, is associated with reduced tumor mass. 
Disruptions to microbial communities, such as reduced α-diversity, are associated with poor 
cancer outcomes.78,100,101 The effects of microbial dysbiosis have been evaluated in a HR+ 
murine model of breast cancer in which α-diversity was reduced via antibiotic treatment and was 
associated with tumor cell dissemination and metastasis.100 A number of clinical trials have also 
found α-diversity and breast cancer to be inversely related.78,101 For instance, Byrd et al. found 
observed SVs, Shannon index, and Faith’s phylogenetic measures in fecal microbial 
communities to all be significantly inversely associated with breast cancer in a case-control 
study.101 A second case-control study also collected fecal samples from patients with breast 
cancer and reported that samples from patients relative to controls had significantly reduced α-
diversity based on the number of observed SVs but not Shannon index.78 Therefore, reduced 
bacterial α-diversity may contribute to both breast cancer risk and progression, though further 
study is needed to evaluate whether a cancer-associated microbial community can be effectively 
manipulated to increase α-diversity and reverse the outcomes of interest. 
Finally, we also found 7 individual genera to be correlated with final tumor mass: 
Acetatifactor, Akkermansia, Anaerotruncus, Butyricimonas, Coprococcus 3, Oscillibacter, and 
Romboutsia (Figure 4F). Of these genera, Akkermansia was particularly interesting given the 
role that Akkermansia muciniphila, a mucin-degrading anaerobic bacteria, is posited to play in 
protection against obesity and inflammation.69,102–106 Interestingly, Akkermansia had the highest 




tumor mass (Figure 4F). However, a positive correlation between Akkermansia and tumor mass 
is contrary to much of the literature which suggests a beneficial role for this genus.84 Despite this 
discrepancy, our finding that Akkermansia is enriched following bariatric surgery is indeed 
consistent with other studies.67,69 In the context of bariatric procedures, Akkermansia is thought 
to mediate improved glucose tolerance and decrease post-surgical inflammation.67,69,107,108 Other 
studies suggest that it may regulate host adiposity and weight loss due to its ability to forage 
mucin during periods of caloric restriction.67,109,110 Therefore, while multiple genera are 
associated with dietary and surgical weight loss interventions, as well as with final tumor mass, 





Overall, our work provides evidence that body weight loss, circulating serum CXCL13 
and PAI-1, and cecal microbial community composition differ following chronic and intermittent 
calorie restriction diets relative to vertical sleeve gastrectomy. These physiological alterations 
may therefore contribute to the improved tumor outcomes we observed in the dietary weight loss 
groups. Future work should consider whether these identified factors affect breast tumor 
progression independently or if they act in combination with each other. Ultimately 
understanding how both metabolic and inflammatory profiles as well as the gut microbiota 
respond to weight loss interventions in the context of breast cancer could eventually lead to 
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